Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Off-Label Communications: US FDA Won't Impede Discussions With Payers, Gottlieb Says

Executive Summary

Guidance, to be issued 'very soon,' will provide a safe harbor for discussions between manufacturers and payers about off-label drug uses, Commissioner Scott Gottlieb says.

You may also be interested in...



Industry Communications With Payors: US FDA Okays Info On Investigational Drugs

Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.

Off-Label Communication: When Does It Align With Approved Labeling?

US FDA draft guidance offers three-factor test to determine when communication about a medical product is consistent with labeling; information on patient-reported outcomes and mechanism of action are okay.

Pfizer Testing Warranty Offer With Xalkori, May Expand It To ‘Multiple’ Products

Company seeks to avoid Medicaid “best price” implications by administering the program through an insurance policy with AIG, which is handling claims for refunds and processing payments.

Topics

UsernamePublicRestriction

Register

PS122955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel